Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-110
- Development stage
- Phase 1
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (with Electroporation)
01
Overview
HB-110 is a **second-generation therapeutic DNA vaccine** in development for chronic hepatitis B infection. It is an **adenoviral-based DNA vaccine** that incorporates a gene fusion for **interleukin-12 (IL-12)** as an immunomodulatory adjuvant. The vaccine is administered via **electroporation**, which aims to increase membrane penetrability and enhance immune response. In clinical trials, HB-110 was combined with nucleos(t)ide analogues (such as adefovir dipivoxil or entecavir). HB-110 was designed to induce HBV-specific T-cell responses, especially CD4+ memory T-cell responses, and promote HBeAg seroconversion. Data have suggested that, while HB-110 is generally well tolerated, its immunogenicity may be lower in some populations due to higher levels of immune tolerance, such as in Korean patients with a high rate of vertical HBV transmission[2][1].
- Brand names
- HB-110HB110HB 110
- Other names
- HB-110HB110HB 110
02
Targets
IL12 (Interleukin-12)
Beyond the preview
Go deeper on HB-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-110.